Pfizer和Merck是价值低估的药品库存,有可能在未来增长。 Pfizer and Merck are undervalued pharmaceutical stocks with potential for future growth.

文章强调Pfizer和Merck是长期投资价值低估的药品库存。 The article highlights Pfizer and Merck as undervalued pharmaceutical stocks for long-term investment. Pfizer面临20%的股票下降,目的是到2028年节省15亿美元,同时增加研发,并将资本返还股东。 Pfizer, facing a 20% stock drop, aims to save $1.5 billion by 2028 while increasing R&D and returning capital to shareholders. Merck尽管经营无利可图,并拥有即将到期的Keyturda专利,但继续大量投资于研发。 Merck, despite operational unprofitability and an expiring Keytruda patent, continues to invest heavily in R&D. 这两家公司的价格与销售比率和价格与无卡什花价比率都较低,表明未来增长的潜力。 Both companies offer low Price-to-Sales and Price-to-Free-Cash-Flow ratios, indicating potential for future growth.